The U.S. market for orthopedic biomaterials grew by 11.5% in 2009, and the hyaluronic acid viscosupplementation (HA) market increased by almost 30%.

The rapid growth of the HA market was due to an increase in use of the three-injection cycle products. Furthermore, the Food and Drug Administration (FDA) approval of Genzyme Biosurgery’s single-injection product, Synvisc-One, is expected to result in significant market changes over the forecast period.

Read more on this interesting market shift in iData Research’s new press release:

Orthopedic Biomaterials Market in the U.S. to Reach Almost $6.3 Billion by 2016